Olga Klaudia Szewczyk-Roszczenko

Mrs. Olga Klaudia Szewczyk-Roszczenko


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RCRobert Czarnomysy
Robert Czarnomysy
Dominika Wioletta RadomskaDominika Wioletta Radomska
Dominika Wioletta Radomska
OSOlga Klaudia Szewczyk-Roszczenko
Olga Klaudia Szewczyk-Roszczenko
Piotr RoszczenkoPiotr Roszczenko
Piotr Roszczenko
KBKrzysztof Bielawski
Krzysztof Bielawski
There is a need for new, safer, and more effective agents to treat cancer. Cytostatics that have transition metals at their core have attracted renewed interest from scientists. Researchers are attempting to use chemotherapeutics, such as cisplatin, in combination therapy (i.e., in order to enhance their effectiveness). Moreover, studies are being carried out to modify molecules, by developing them into multinuclear structures, linking different compounds to commonly used drugs, or encapsulating them in nanoparticles to improve pharmacokinetic parameters, and increase the selectivity of these drugs. Therefore, we attempted to organize recent drug findings that contain palladium and platinum atoms in their structures.

Verified
Journal Article
Open access
PDF file
Piotr RoszczenkoPiotr Roszczenko
Piotr Roszczenko
Serhii HolotaSerhii Holota
Serhii Holota
OSOlga Klaudia Szewczyk-Roszczenko
Olga Klaudia Szewczyk-Roszczenko
RDRostyslav Dudchak
Rostyslav Dudchak
KBKrzysztof Bielawski
Krzysztof Bielawski
Roman LesykRoman Lesyk
Roman Lesyk
Oncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal chemistry focused on the research and development of novel effective anticancer drugs. In this review, the data concerning new 4-thiazolidinone-bearing hybrid molecules with potential anticancer activity reported during the period from the years 2017–2022 are summarized. The main emphasis is on the application of molecular hybridization methodologies and strategies in the design of small molecules as anticancer agents. Based on the analyzed data, it was observed that the main directions in this field are the hybridization of scaffolds, the hybrid-pharmacophore approach, and the analogue-based drug design of 4-thiazolidinone cores with early approved drugs, natural compounds, and privileged heterocyclic scaffolds. The mentioned design approaches are effective tools/sources for the generation of hit/lead compounds with anticancer activity and will be relevant to future studies.

19 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
OSOlga Klaudia Szewczyk-Roszczenko
Olga Klaudia Szewczyk-Roszczenko
Piotr RoszczenkoPiotr Roszczenko
Piotr Roszczenko
ASAnna Shmakova
Anna Shmakova
Nataliya FiniukNataliya Finiuk
Nataliya Finiuk
Serhii HolotaSerhii Holota
Serhii Holota
KBKrzysztof Bielawski
Krzysztof Bielawski
Endocytosis is one of the major ways cells communicate with their environment. This process is frequently hijacked by pathogens. Endocytosis also participates in the oncogenic transformation. Here, we review the approaches to inhibit endocytosis, discuss chemical inhibitors of this process, and discuss potential clinical applications of the endocytosis inhibitors.

Verified
Journal Article
Open access
PDF file
OSOlga Klaudia Szewczyk-Roszczenko
Olga Klaudia Szewczyk-Roszczenko
Piotr RoszczenkoPiotr Roszczenko
Piotr Roszczenko
RCRobert Czarnomysy
Robert Czarnomysy
ABAnna Bielawska
Anna Bielawska
KBKrzysztof Bielawski
Krzysztof Bielawski
Several authorities have implied that nanotechnology has a significant future in the development of advanced cancer therapies. Nanotechnology makes it possible to simultaneously administer drug combinations and engage the immune system to fight cancer. Nanoparticles can locate metastases in different organs and deliver medications to them. Using them allows for the effective reduction of tumors with minimal toxicity to healthy tissue. Transition-metal nanoparticles, through Fenton-type or Haber–Weiss-type reactions, generate reactive oxygen species. Through oxidative stress, the particles induce cell death via different pathways. The main limitation of the particles is their toxicity. Certain factors can control toxicity, such as route of administration, size, aggregation state, surface functionalization, or oxidation state. In this review, we attempt to discuss the effects and toxicity of transition-metal nanoparticles.

25 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Piotr RoszczenkoPiotr Roszczenko
Piotr Roszczenko
OSOlga Klaudia Szewczyk-Roszczenko
Olga Klaudia Szewczyk-Roszczenko
RCRobert Czarnomysy
Robert Czarnomysy
KBKrzysztof Bielawski
Krzysztof Bielawski
ABAnna Bielawska
Anna Bielawska
Nanomedicine is a potential provider of novel therapeutic and diagnostic routes of treatment. Considering the development of multidrug resistance in pathogenic bacteria and the commonness of cancer, novel approaches are being sought for the safe and efficient synthesis of new nanoparticles, which have multifaceted applications in medicine. Unfortunately, the chemical synthesis of nanoparticles raises justified environmental concerns. A significant problem in their widespread use is also the toxicity of compounds that maintain nanoparticle stability, which significantly limits their clinical use. An opportunity for their more extensive application is the utilization of plants, fungi, and bacteria for nanoparticle biosynthesis. Extracts from natural sources can reduce metal ions in nanoparticles and stabilize them with non-toxic extract components.

Verified
Journal Article
Open access
PDF file
JKJan Koptielow
Jan Koptielow
ESEmilia Szyłak
Emilia Szyłak
OSOlga Klaudia Szewczyk-Roszczenko
Olga Klaudia Szewczyk-Roszczenko
Piotr RoszczenkoPiotr Roszczenko
Piotr Roszczenko
JKJan Kochanowicz
Jan Kochanowicz
MCMonika Chorąży
Monika Chorąży
A neurological condition called dystonia results in abnormal, uncontrollable postures or movements because of sporadic or continuous muscular spasms. Several varieties of dystonia can impact people of all ages, leading to severe impairment and a decreased standard of living. The discovery of genes causing variations of single or mixed dystonia has improved our understanding of the disease’s etiology. Genetic dystonias are linked to several genes, including pathogenic variations of VPS16, TOR1A, THAP1, GNAL, and ANO3. Diagnosis of dystonia is primarily based on clinical symptoms, which can be challenging due to overlapping symptoms with other neurological conditions, such as Parkinson’s disease. This review aims to summarize recent advances in the genetic origins and management of focal dystonia.